← Retour à la une
États-Unis · Plateformes & données · Yahoo Finance

PacBio (PACB) Stock Sees Split Analyst Revisions As Fair Value Edges Higher

Publié par Yahoo Finance · États-Unis il y a 9 h
NasdaqGS:PACB 1-Year Stock Price Chart
NasdaqGS:PACB 1-Year Stock Price Chart · Yahoo Finance

Résumé détaillé

Recent analyst revisions have brought Pacific Biosciences of California into focus as price targets have shifted into a tighter band around the US$2 to US$2.70 range. These…

Recent analyst revisions have brought Pacific Biosciences of California into focus as price targets have shifted into a tighter band around the US$2 to US$2.70 range. These changes reflect updated views from both more optimistic and more cautious analysts who are reassessing the stock as new earnings previews and sector comparisons come through. As you read on, you will see how these moving targets fit into the broader story and how to track the evolving narrative around Pacific Biosciences of California.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Pacific Biosciences of California.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!

We've flagged 3 risks for Pacific Biosciences of California. See which could impact your investment.

Narratives link Pacific Biosciences of California's business story to a financial forecast and fair value that update as new data arrives. They help you see how clinical, product and funding developments fit together over time.

Head over to the Simply Wall St Community and follow the Narrative on Pacific Biosciences of California to stay up to date on:

This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article?

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

À lire aussi